Modality
Small Molecule
MOA
KRASG12Ci
Target
GPRC5D
Pathway
NF-κB
Cervical Ca
Development Pipeline
Preclinical
~Aug 2019
→ ~Nov 2020
Phase 1
~Feb 2021
→ ~May 2022
Phase 2
Aug 2022
→ Oct 2028
Phase 2Current
NCT08602061
599 pts·Cervical Ca
2023-11→2028-10·Active
NCT04607431
113 pts·Cervical Ca
2022-08→TBD·Active
712 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-242.6y awayPh3 Readout· Cervical Ca
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Active
P2/3
Active
Catalysts
Ph3 Readout
2028-10-24 · 2.6y away
Cervical Ca
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08602061 | Phase 2/3 | Cervical Ca | Active | 599 | FEV1 |
| NCT04607431 | Phase 2/3 | Cervical Ca | Active | 113 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |